

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

### **中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **BUSINESS UPDATE ON THE MEDICAL LABORATORY TESTING BUSINESS**

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group has partnered with BGI Health (HK) Company Limited to incorporate Sunrise Diagnostic Centre Limited (華昇診斷中心有限公司) (“**Sunrise Diagnostic Centre**”), a company based in Hong Kong and principally engaged in the provision of medical laboratory testing services in Hong Kong.

Sunrise Diagnostic Centre has previously set up a laboratory in Hong Kong for novel coronavirus (“**Covid-19**”) testing and has recently set up and operate an additional temporary laboratory with 16 air membrane in Hong Kong to provide Covid-19 tests to Hong Kong citizens to find the silent carriers. The additional laboratory can conduct around 100,000 single-tube tests per day, which will increase the total testing capacity of Sunrise Diagnostic Centre from 30,000 to 130,000 tests per day, making it one of the laboratories with high testing capacity for Covid-19 testing in Hong Kong. As at the date of this announcement, Sunrise Diagnostic Centre has performed more than 100,000 Covid-19 tests.

The Board considers that the newly set up designated laboratory will play a key role in the community testing and screening for Covid-19 and cooperate with the government's plan on mass Covid-19 testing. Furthermore, Sunrise Diagnostic Centre are well prepared for the development of the health code system in Hong Kong in the future for the recovery of economy and the tourism industry and lifting the border restrictions.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Co-Chairman and Executive Director*

Hong Kong, 17 August 2020

*As at the date of this announcement, the board of Directors comprises six executive Directors, namely, Mr. Liu Xiaolin (Co-Chairman), Mr. Yao Michael Yi (Co-Chairman), Mr. He Xun, Mr. Huang Song, Mr. Leung Pak Hou Anson and Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company information" page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*